Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial

被引:0
作者
Christian T. Ruff
Michelle Baron
KyungAh Im
Michelle L. O’Donoghue
Fred T. Fiedorek
Marc S. Sabatine
机构
[1] Brigham and Women’s Hospital,TIMI Study Group, Division of Cardiovascular Medicine
[2] Harvard Medical School,undefined
[3] Intarcia Therapeutics,undefined
来源
Nature Medicine | 2022年 / 28卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) injected periodically have been shown to not increase and, for some members of this class, decrease the risk of cardiovascular events. The cardiovascular safety of delivering a continuous subcutaneous infusion of the GLP-1RA exenatide (ITCA 650) is unknown. Here, we randomly assigned patients with type 2 diabetes with, or at risk for, atherosclerotic cardiovascular disease (ASCVD) to receive ITCA 650 or placebo to assess cardiovascular safety in a pre-approval trial (NCT01455896). The primary outcome was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for unstable angina. On the basis of 2008 guidance from the US Food and Drug Administration, a non-inferiority margin of 1.8 for the upper bound of the 95% confidence interval (CI) of the hazard ratio (HR) was used. We randomized 4,156 patients (2,075 assigned to receive ITCA 650 and 2,081 assigned to receive placebo) who were followed for a median of 16 months. The primary outcome occurred in 4.6% (95/2,075) of patients in the ITCA 650 group and 3.8% (79/2,081) of patients in the placebo group, meeting the pre-specified non-inferiority criterion (HR = 1.21, 95% CI, 0.90–1.63, Pnon-inferiority = 0.004). Serious adverse events were similar between the two groups. Adverse events were more frequent in the ITCA 650 group (72%, 1,491/2,074) than in the placebo group (63.9%, 1,325/2,070), mainly due to an increase in gastrointestinal events and disorders while on ITCA 650. In patients with type 2 diabetes with, or at risk for, ASCVD, ITCA 650 was non-inferior to placebo. A larger and longer-duration cardiovascular outcomes trial is needed to define more precisely the cardiovascular effects of ITCA 650 in this population.
引用
收藏
页码:89 / 95
页数:6
相关论文
共 24 条
[21]  
Foulkes MA(undefined)undefined undefined undefined undefined-undefined
[22]  
Rothmann M(undefined)undefined undefined undefined undefined-undefined
[23]  
O’Brien PC(undefined)undefined undefined undefined undefined-undefined
[24]  
Fleming TR(undefined)undefined undefined undefined undefined-undefined